![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SATB1 |
Gene summary for SATB1 |
![]() |
Gene information | Species | Human | Gene symbol | SATB1 | Gene ID | 6304 |
Gene name | SATB homeobox 1 | |
Gene Alias | DEFDA | |
Cytomap | 3p24.3 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | A0A024R2H1 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6304 | SATB1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.81e-06 | 1.64e-01 | 0.0155 |
6304 | SATB1 | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.14e-02 | 1.26e-01 | -0.1808 |
6304 | SATB1 | HTA11_2951_2000001011 | Human | Colorectum | AD | 3.40e-03 | 2.22e-01 | 0.0216 |
6304 | SATB1 | HTA11_1938_2000001011 | Human | Colorectum | AD | 2.86e-06 | 2.21e-01 | -0.0811 |
6304 | SATB1 | HTA11_78_2000001011 | Human | Colorectum | AD | 8.35e-11 | 3.25e-01 | -0.1088 |
6304 | SATB1 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.88e-15 | 3.08e-01 | -0.1954 |
6304 | SATB1 | HTA11_411_2000001011 | Human | Colorectum | SER | 5.61e-03 | 2.94e-01 | -0.2602 |
6304 | SATB1 | HTA11_696_2000001011 | Human | Colorectum | AD | 3.61e-02 | 9.39e-02 | -0.1464 |
6304 | SATB1 | HTA11_866_2000001011 | Human | Colorectum | AD | 2.00e-05 | 1.56e-01 | -0.1001 |
6304 | SATB1 | HTA11_1391_2000001011 | Human | Colorectum | AD | 4.63e-07 | 2.38e-01 | -0.059 |
6304 | SATB1 | HTA11_7862_2000001011 | Human | Colorectum | AD | 1.01e-11 | 3.55e-01 | -0.0179 |
6304 | SATB1 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.21e-15 | 3.04e-01 | 0.096 |
6304 | SATB1 | HTA11_8622_2000001021 | Human | Colorectum | SER | 4.45e-03 | 2.67e-01 | 0.0528 |
6304 | SATB1 | HTA11_7663_2000001011 | Human | Colorectum | SER | 7.76e-07 | 4.31e-01 | 0.0131 |
6304 | SATB1 | HTA11_10623_2000001011 | Human | Colorectum | AD | 9.21e-08 | 3.35e-01 | -0.0177 |
6304 | SATB1 | HTA11_6801_2000001011 | Human | Colorectum | SER | 2.21e-02 | 2.06e-01 | 0.0171 |
6304 | SATB1 | HTA11_10711_2000001011 | Human | Colorectum | AD | 9.64e-06 | 2.21e-01 | 0.0338 |
6304 | SATB1 | HTA11_7696_3000711011 | Human | Colorectum | AD | 7.82e-13 | 2.89e-01 | 0.0674 |
6304 | SATB1 | HTA11_6818_2000001011 | Human | Colorectum | AD | 2.70e-04 | 2.38e-01 | 0.0112 |
6304 | SATB1 | HTA11_7469_2000001011 | Human | Colorectum | AD | 3.81e-02 | 2.45e-01 | -0.0124 |
Page: 1 2 3 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0006325 | Colorectum | AD | chromatin organization | 119/3918 | 409/18723 | 4.85e-05 | 8.33e-04 | 119 |
GO:0006338 | Colorectum | AD | chromatin remodeling | 70/3918 | 255/18723 | 7.44e-03 | 4.53e-02 | 70 |
GO:00063251 | Colorectum | SER | chromatin organization | 89/2897 | 409/18723 | 4.15e-04 | 6.17e-03 | 89 |
GO:00063252 | Colorectum | MSS | chromatin organization | 107/3467 | 409/18723 | 7.22e-05 | 1.21e-03 | 107 |
GO:000632511 | Liver | HCC | chromatin organization | 206/7958 | 409/18723 | 7.23e-04 | 4.41e-03 | 206 |
GO:000632514 | Prostate | Tumor | chromatin organization | 104/3246 | 409/18723 | 2.02e-05 | 2.62e-04 | 104 |
GO:000633811 | Prostate | Tumor | chromatin remodeling | 63/3246 | 255/18723 | 1.73e-03 | 1.02e-02 | 63 |
GO:000632520 | Thyroid | PTC | chromatin organization | 183/5968 | 409/18723 | 2.55e-08 | 5.70e-07 | 183 |
GO:00063385 | Thyroid | PTC | chromatin remodeling | 106/5968 | 255/18723 | 6.56e-04 | 4.13e-03 | 106 |
GO:0006325110 | Thyroid | ATC | chromatin organization | 189/6293 | 409/18723 | 6.40e-08 | 1.13e-06 | 189 |
GO:000633813 | Thyroid | ATC | chromatin remodeling | 109/6293 | 255/18723 | 1.38e-03 | 7.15e-03 | 109 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SATB1 | SNV | Missense_Mutation | c.1564N>T | p.Thr522Ser | p.T522S | Q01826 | protein_coding | tolerated(1) | benign(0.009) | TCGA-A8-A081-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SATB1 | SNV | Missense_Mutation | novel | c.943N>A | p.Gln315Lys | p.Q315K | Q01826 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SATB1 | SNV | Missense_Mutation | c.1576N>A | p.Gly526Arg | p.G526R | Q01826 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AR-A250-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
SATB1 | SNV | Missense_Mutation | c.2239G>A | p.Asp747Asn | p.D747N | Q01826 | protein_coding | deleterious(0.04) | benign(0.014) | TCGA-B6-A0X5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
SATB1 | SNV | Missense_Mutation | novel | c.2284N>A | p.Glu762Lys | p.E762K | Q01826 | protein_coding | deleterious(0) | benign(0.288) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SATB1 | SNV | Missense_Mutation | rs755807693 | c.857N>T | p.Ala286Val | p.A286V | Q01826 | protein_coding | tolerated(0.48) | benign(0.006) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SATB1 | SNV | Missense_Mutation | c.748N>G | p.Met250Val | p.M250V | Q01826 | protein_coding | tolerated(0.2) | benign(0.019) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
SATB1 | SNV | Missense_Mutation | c.266N>G | p.Tyr89Cys | p.Y89C | Q01826 | protein_coding | tolerated(0.16) | possibly_damaging(0.773) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
SATB1 | SNV | Missense_Mutation | c.317N>A | p.Leu106His | p.L106H | Q01826 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-E2-A14W-01 | Breast | breast invasive carcinoma | Male | >=65 | I/II | Chemotherapy | cytoxan | SD | |
SATB1 | SNV | Missense_Mutation | novel | c.2383G>C | p.Asp795His | p.D795H | Q01826 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.642) | TCGA-E9-A1RF-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |